{"doi":"10.1002/bmc.5643","title":"LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies","abstract":"Abstract A sensitive and selective liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantitation of dual PI3K/BRD4 inhibitor SF2523 in mouse plasma. The analysis was performed on a UPLC system connected to a Shimadzu 8060 mass spectrometer by electrospray ionization in positive multiple reaction monitoring mode. Chromatographic separation was carried out on an ACE Excel C 18 column with a gradient elution containing 0.1% formic acid and methanol as the mobile phase. The linearity was conducted in the concentration range 0.1–500 ng/ml for SF2523 in 100 μl of plasma. The inter‐ and intra‐batch precision (RSD) were both lower than 13.5%, with the accuracy (percentage bias) ranging from −10.03 to 11.56%. The validated method was successfully applied to plasma protein binding and in vitro metabolism studies. SF2523 was highly bound to mouse plasma proteins (>95% bound). Utilizing mouse S9 fractions, a total of seven phase I and II metabolites were identified with hydroxylation found to be the major metabolic pathway. Metabolite identification included analysis of retention behaviors, molecular weight changes and MS/MS fragment patterns of SF2523 and the metabolites. This newly developed and validated method allows the rapid and easy determination of the SF2523 concentration with high sensitivity in a low sample volume and can be applied to future pre‐clinical studies.","journal":"Biomedical Chromatography","year":2023,"id":376781,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9515,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":264857,"name":"Yashpal S. Chhonker","orcid":"0000-0001-6455-5388","position":1,"is_corresponding":false},{"id":417244,"name":"Guillermo Morales","orcid":null,"position":2,"is_corresponding":false},{"id":954148,"name":"Maddeboina Krishnaiah","orcid":"0009-0000-4385-9788","position":3,"is_corresponding":false},{"id":416601,"name":"Dhananjaya Pal","orcid":"0000-0001-7675-4819","position":4,"is_corresponding":false},{"id":267282,"name":"Donald L. Durden","orcid":"0000-0001-5386-1427","position":5,"is_corresponding":false},{"id":264865,"name":"Daryl J. Murry","orcid":"0000-0002-4169-5027","position":6,"is_corresponding":false},{"id":419424,"name":"Veenu Bala","orcid":null,"position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-19T01:16:32.368674Z","pmid":"37042063","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}